Precision BioSciences Inc . (NASDAQ:DTIL), a profitable gene editing company with a market capitalization of $38.7 million, has announced the retirement of Dr. Sam Wadsworth from its Board of ...
Dario Scimeca, General Counsel and Secretary of Precision BioSciences Inc . (NASDAQ:DTIL), a biotechnology company with a market capitalization of $38 million and currently trading at $4.97, executed ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
SQZ Biotechnologies (NYSE:SQZ – Get Free Report) and Precision BioSciences (NASDAQ:DTIL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast ...
Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company”), a life sciences company developing precision genetic medicines for ...
The innovation, he says, could transform the way scientists measure and address genomic breaks in gene-editing systems.
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene ...
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback